Co-Authors
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and VINOD RAVI.
Connection Strength
0.733
-
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21.
Score: 0.202
-
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
Score: 0.135
-
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
Score: 0.058
-
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
Score: 0.057
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.047
-
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
Score: 0.044
-
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
Score: 0.041
-
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963.
Score: 0.040
-
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
Score: 0.039
-
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
Score: 0.037
-
Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53.
Score: 0.033